159 related articles for article (PubMed ID: 26139656)
1. Treatment failure by canakinumab in a patient with progressive multisystemic Erdheim-Chester disease refractory to anakinra: successful use of vemurafenib.
Schirmer JH; Thorns C; Moosig F; Holle JU
Rheumatology (Oxford); 2015 Oct; 54(10):1932-4. PubMed ID: 26139656
[No Abstract] [Full Text] [Related]
2. Successful treatment of Erdheim-Chester disease by interleukin-1 receptor antagonist protein.
Courcoul A; Vignot E; Chapurlat R
Joint Bone Spine; 2014 Mar; 81(2):175-7. PubMed ID: 23953221
[TBL] [Abstract][Full Text] [Related]
3. Marked efficacy of vemurafenib in suprasellar Erdheim-Chester disease.
Cohen-Aubart F; Emile JF; Maksud P; Galanaud D; Idbaih A; Chauvet D; Amar Y; Benameur N; Amoura Z; Haroche J
Neurology; 2014 Sep; 83(14):1294-6. PubMed ID: 25171932
[No Abstract] [Full Text] [Related]
4. [Evaluation of five years of treatment of Erdheim-Chester disease with anakinra: case report and overview of literature].
Adam Z; Petrášová H; Řehák Z; Koukalová R; Krejčí M; Pour L; Vetešníková E; Čermák A; Ševčíková S; Szturz P; Král Z; Mayer J
Vnitr Lek; 2016; 62(10):820-832. PubMed ID: 27900869
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Erdheim-Chester disease with canakinumab.
Tran TA; Pariente D; Guitton C; Delwail A; Barat-Houari M; Meinzer U
Rheumatology (Oxford); 2014 Dec; 53(12):2312-4. PubMed ID: 25234662
[No Abstract] [Full Text] [Related]
6. Treatment of pediatric Erdheim-Chester disease with interleukin-1-targeting drugs.
Tran TA; Pariente D; Lecron JC; Delwail A; Taoufik Y; Meinzer U
Arthritis Rheum; 2011 Dec; 63(12):4031-2. PubMed ID: 21898344
[No Abstract] [Full Text] [Related]
7. Favorable radiological outcome of skeletal Erdheim-Chester disease involvement with anakinra.
Aubert O; Aouba A; Deshayes S; Georgin-Lavialle S; Rieu P; Hermine O
Joint Bone Spine; 2013 Mar; 80(2):206-7. PubMed ID: 22999905
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of cutaneous-onset Erdheim-Chester disease with cobimetinib and anakinra.
Aromolo IF; Moltrasio C; Maronese CA; Campochiaro C; Bonometti A; Berti E; Passoni E; Marzano A
Clin Exp Dermatol; 2024 Apr; 49(5):523-525. PubMed ID: 38231013
[No Abstract] [Full Text] [Related]
9. Erdheim-Chester disease with cardiac involvement successfully treated with anakinra.
Killu AM; Liang JJ; Jaffe AS
Int J Cardiol; 2013 Sep; 167(5):e115-7. PubMed ID: 23659884
[No Abstract] [Full Text] [Related]
10. Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: Towards the paradigm of combined targeting and immune therapies.
Franconieri F; Martin-Silva N; de Boysson H; Galateau-Salle F; Emile JF; Bienvenu B; Aouba A
Acta Oncol; 2016 Jul; 55(7):930-2. PubMed ID: 27031008
[No Abstract] [Full Text] [Related]
11. Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study).
Cohen Aubart F; Emile JF; Carrat F; Charlotte F; Benameur N; Donadieu J; Maksud P; Idbaih A; Barete S; Hoang-Xuan K; Amoura Z; Haroche J
Blood; 2017 Sep; 130(11):1377-1380. PubMed ID: 28667012
[No Abstract] [Full Text] [Related]
12. Anakinra-responsive lichen planus in a woman with Erdheim-Chester disease: a therapeutic enigma.
Cohen PR; Kurzrock R
Dermatol Online J; 2014 Jan; 20(1):21241. PubMed ID: 24456945
[TBL] [Abstract][Full Text] [Related]
13. Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report.
Tzoulis C; Schwarzlmüller T; Gjerde IO; Søfteland E; Neckelmann G; Biermann M; Haroche J; Straume O; Vintermyr OK
BMC Res Notes; 2015 Apr; 8():171. PubMed ID: 25926131
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Continuous Interleukin 1 Blockade in Mevalonate Kinase Deficiency: A Multicenter Retrospective Study in 13 Adult Patients and Literature Review.
Deshayes S; Georgin-Lavialle S; Hot A; Durel CA; Hachulla E; Rouanes N; Audia S; Le Gallou T; Quartier P; Urbanski G; Messer L; Klein S; de Boysson H; Bienvenu B; Grateau G; Aouba A
J Rheumatol; 2018 Mar; 45(3):425-429. PubMed ID: 29335349
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of Erdheim-Chester disease with combination of interleukin-1-targeting drugs and high-dose glucocorticoids.
Darstein F; Kirschey S; Heckl S; Rahman F; Schwarting A; Schuchmann M; Galle PR; Zimmermann T
Intern Med J; 2014 Jan; 44(1):90-2. PubMed ID: 24450524
[TBL] [Abstract][Full Text] [Related]
16. Orbital MRI Pre- and Post-Vemurafenib Therapy for Erdheim-Chester Disease.
Grumbine FL; Aderman C; Vagefi MR; Kersten RC
Ophthalmic Plast Reconstr Surg; 2015; 31(6):e169. PubMed ID: 25886699
[No Abstract] [Full Text] [Related]
17. Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome.
Kahn PJ; Cron RQ
J Rheumatol; 2013 May; 40(5):743-4. PubMed ID: 23637382
[No Abstract] [Full Text] [Related]
18. [Update in interleukin-1 inhibition].
de Boysson H
Rev Med Interne; 2012 Apr; 33(4):235-7. PubMed ID: 22360831
[No Abstract] [Full Text] [Related]
19. Vemurafenib (BRAF Inhibitor) Therapy for Orbital Erdheim-Chester Disease.
Gupta A; Yeganeh A; Rootman D; Goldberg R
Ophthalmic Plast Reconstr Surg; 2017; 33(6):e138-e139. PubMed ID: 28099231
[TBL] [Abstract][Full Text] [Related]
20. Successful response in a case of severe pustular psoriasis after interleukin-1β inhibition.
Skendros P; Papagoras C; Lefaki I; Giatromanolaki A; Kotsianidis I; Speletas M; Bocly V; Theodorou I; Dalla V; Ritis K
Br J Dermatol; 2017 Jan; 176(1):212-215. PubMed ID: 27105586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
